Compare CHMI & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | SAVA |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 96.1M |
| IPO Year | 2013 | N/A |
| Metric | CHMI | SAVA |
|---|---|---|
| Price | $2.62 | $2.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $5.00 |
| AVG Volume (30 Days) | 177.5K | ★ 772.9K |
| Earning Date | 03-05-2026 | 03-02-2026 |
| Dividend Yield | ★ 15.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $40,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.73 | N/A |
| P/E Ratio | $138.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $1.15 |
| 52 Week High | $3.68 | $4.98 |
| Indicator | CHMI | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 47.99 |
| Support Level | $2.54 | $2.04 |
| Resistance Level | $2.63 | $2.22 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 12.00 | 62.86 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.